Alpha-9 Theranostics, a Boston, MA- and Vancouver, Canada-based clinical stage radiopharmaceutical company, raised $75M in Series B funding.
The round was led by Nextech Invest, with participation from Frazier Life Sciences, Samsara BioCapital, Quark Venture, Longitude Capital, and BVF Partners. Melissa McCracken, Ph.D., Partner at Nextech Invest, Patrick Heron, M.B.A., Managing Partner at Frazier Life Sciences, Cory Freedland, Ph.D., Partner at Samsara BioCapital, and Matthew Young, M.B.A., Managing Director at Longitude Capital will join the Alpha-9 Board of Directors, along with Darcy Mootz, Ph.D., Site Head at Amunix, a Sanofi Company (Chief Business Officer prior to sale), who will join as a Board advisor.
The company intends to use the funds to support advancement of its five programs into the clinic over the next two years while expanding its early-stage programs.
Founded in 2019 by François Bénard, M.D., Kuo-Shyan Lin, Ph.D., and David Perrin, Ph.D., researchers from BC Cancer and the University of British Columbia with deep expertise in the modification of peptides and small-molecules to create novel radiopharmaceuticals, Alpha-9 Theranostics is developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and expertise, the company is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets.
FinSMEs
15/12/2022